Cardiac Versus Renal Response to Volume Expansion in Preclinical Systolic Dysfunction With PDEV Inhibition and BNP
| Autor: | John C. Burnett, Joshua P. Slusser, David O. Hodge, Isabel Torres-Courchoud, Paul M. McKie, Margaret M. Redfield, Horng H. Chen, Siu Hin Wan |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Nesiritide Cardiac function curve lcsh:Diseases of the circulatory (Cardiovascular) system medicine.medical_specialty Ejection fraction business.industry medicine.drug_class Renal function 030204 cardiovascular system & hematology medicine.disease Tadalafil 03 medical and health sciences 030104 developmental biology 0302 clinical medicine lcsh:RC666-701 Heart failure Internal medicine Renal blood flow medicine Cardiology Natriuretic peptide Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | JACC: Basic to Translational Science, Vol 4, Iss 8, Pp 962-972 (2019) |
| ISSN: | 2452-302X |
| DOI: | 10.1016/j.jacbts.2019.08.008 |
| Popis: | Summary: Impaired cardiorenal response to acute saline volume expansion in preclinical systolic dysfunction (PSD) may lead to symptomatic heart failure. The objective was to determine if combination phosphodiesterase-V inhibition and exogenous B-type natriuretic peptide (BNP) administration may enhance cardiorenal response. A randomized double-blinded, placebo-controlled study was conducted in 21 subjects with PSD and renal dysfunction. Pre-treatment with tadalafil and subcutaneous BNP resulted in improved cardiac function, as evidenced by improvement in ejection fraction, left atrial volume index, and left ventricular end-diastolic volume. However, there was reduced renal response with reduction in renal plasma flow, glomerular filtration rate, and urine flow. (Tadalafil and Nesiritide as Therapy in Pre-clinical Heart Failure; NCT01544998) Key Words: B-type natriuretic peptide, cardiorenal, heart failure, nesiritide, phosphodiesterase inhibition, systolic dysfunction |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|